Cargando…

Subcutaneous amyloidoma models for screening potential anti-fibrillating agents in vivo

Here, we describe a robust protocol using mouse models to screen potential insulin-stabilizers and insulin moieties. We have generated a mouse model of amyloidoma, found in diabetic patients undergoing insulin therapy. This model can be used to screen potential insulin stabilizers and insulin moieti...

Descripción completa

Detalles Bibliográficos
Autores principales: Das, Debajyoti, Paul, Avishek, Maity, Sujay Krishna, Chatterjee, Subhrangsu, Chakrabarti, Partha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8683767/
https://www.ncbi.nlm.nih.gov/pubmed/34977673
http://dx.doi.org/10.1016/j.xpro.2021.101027
_version_ 1784617486987034624
author Das, Debajyoti
Paul, Avishek
Maity, Sujay Krishna
Chatterjee, Subhrangsu
Chakrabarti, Partha
author_facet Das, Debajyoti
Paul, Avishek
Maity, Sujay Krishna
Chatterjee, Subhrangsu
Chakrabarti, Partha
author_sort Das, Debajyoti
collection PubMed
description Here, we describe a robust protocol using mouse models to screen potential insulin-stabilizers and insulin moieties. We have generated a mouse model of amyloidoma, found in diabetic patients undergoing insulin therapy. This model can be used to screen potential insulin stabilizers and insulin moieties to prevent amyloidoma formation. This protocol can further be used for the preclinical validation of therapeutically relevant insulin stabilizers and formulations. The protocol highlights all the critical steps for generating amyloidoma in a preclinical model. For complete details on the use and execution of this profile, please refer to Mukherjee et al. (2021).
format Online
Article
Text
id pubmed-8683767
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-86837672021-12-30 Subcutaneous amyloidoma models for screening potential anti-fibrillating agents in vivo Das, Debajyoti Paul, Avishek Maity, Sujay Krishna Chatterjee, Subhrangsu Chakrabarti, Partha STAR Protoc Protocol Here, we describe a robust protocol using mouse models to screen potential insulin-stabilizers and insulin moieties. We have generated a mouse model of amyloidoma, found in diabetic patients undergoing insulin therapy. This model can be used to screen potential insulin stabilizers and insulin moieties to prevent amyloidoma formation. This protocol can further be used for the preclinical validation of therapeutically relevant insulin stabilizers and formulations. The protocol highlights all the critical steps for generating amyloidoma in a preclinical model. For complete details on the use and execution of this profile, please refer to Mukherjee et al. (2021). Elsevier 2021-12-14 /pmc/articles/PMC8683767/ /pubmed/34977673 http://dx.doi.org/10.1016/j.xpro.2021.101027 Text en © 2021 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Protocol
Das, Debajyoti
Paul, Avishek
Maity, Sujay Krishna
Chatterjee, Subhrangsu
Chakrabarti, Partha
Subcutaneous amyloidoma models for screening potential anti-fibrillating agents in vivo
title Subcutaneous amyloidoma models for screening potential anti-fibrillating agents in vivo
title_full Subcutaneous amyloidoma models for screening potential anti-fibrillating agents in vivo
title_fullStr Subcutaneous amyloidoma models for screening potential anti-fibrillating agents in vivo
title_full_unstemmed Subcutaneous amyloidoma models for screening potential anti-fibrillating agents in vivo
title_short Subcutaneous amyloidoma models for screening potential anti-fibrillating agents in vivo
title_sort subcutaneous amyloidoma models for screening potential anti-fibrillating agents in vivo
topic Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8683767/
https://www.ncbi.nlm.nih.gov/pubmed/34977673
http://dx.doi.org/10.1016/j.xpro.2021.101027
work_keys_str_mv AT dasdebajyoti subcutaneousamyloidomamodelsforscreeningpotentialantifibrillatingagentsinvivo
AT paulavishek subcutaneousamyloidomamodelsforscreeningpotentialantifibrillatingagentsinvivo
AT maitysujaykrishna subcutaneousamyloidomamodelsforscreeningpotentialantifibrillatingagentsinvivo
AT chatterjeesubhrangsu subcutaneousamyloidomamodelsforscreeningpotentialantifibrillatingagentsinvivo
AT chakrabartipartha subcutaneousamyloidomamodelsforscreeningpotentialantifibrillatingagentsinvivo